Article: Merck and Bristol-Myers Squibb License New AIDS Drugs to IPM for Development as Microbicides to Protect Women from HIV.

NEW YORK, October 31 /PRNewswire/ --

- New Nature study shows potential of 'entry inhibitor' compounds as HIV prevention tool

In a first-of-its-kind joint announcement, two of the world's leading pharmaceutical companies, Merck & Co., Inc. and Bristol-Myers Squibb have each announced today that they have signed separate license agreements with the International Partnership for Microbicides (IPM) to develop new antiretroviral compounds as potential microbicides to protect women from HIV. Under the two separate agreements, Merck and Bristol-Myers Squibb will each grant the non-profit group a royalty-free license to develop, manufacture and ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!